Novavax, Inc. (NASDAQ:NVAX) Stock Holdings Decreased by Vontobel Holding Ltd.

Vontobel Holding Ltd. reduced its stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 82.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,820 shares of the biopharmaceutical company's stock after selling 354,917 shares during the period. Vontobel Holding Ltd.'s holdings in Novavax were worth $486,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of NVAX. Bank of New York Mellon Corp lifted its position in shares of Novavax by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock worth $3,509,000 after buying an additional 1,664 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Novavax by 3.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,365,414 shares of the biopharmaceutical company's stock valued at $10,978,000 after purchasing an additional 39,906 shares during the last quarter. Arizona State Retirement System lifted its position in Novavax by 14.9% in the 4th quarter. Arizona State Retirement System now owns 41,793 shares of the biopharmaceutical company's stock valued at $336,000 after purchasing an additional 5,407 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Novavax in the 4th quarter valued at about $544,000. Finally, E Fund Management Co. Ltd. lifted its position in Novavax by 5.1% in the 4th quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company's stock valued at $204,000 after purchasing an additional 1,219 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. B. Riley reiterated a "buy" rating on shares of Novavax in a research report on Monday, May 19th. JPMorgan Chase & Co. cut their price objective on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research report on Friday, May 9th. Finally, Citigroup assumed coverage on shares of Novavax in a research report on Tuesday, June 17th. They issued a "sell" rating and a $6.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $17.00.

Novavax Price Performance

Shares of NVAX traded up $0.43 during mid-day trading on Tuesday, hitting $7.04. The company's stock had a trading volume of 7,076,297 shares, compared to its average volume of 6,300,108. The firm has a 50-day moving average price of $6.76 and a 200 day moving average price of $7.45. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of 2.66, a PEG ratio of 0.06 and a beta of 2.69. Novavax, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $17.81.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $2.22. The company had revenue of $666.66 million for the quarter, compared to analysts' expectations of $204.08 million. Novavax had a net margin of 38.14% and a negative return on equity of 115.51%. The business's revenue was up 610.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.05) EPS. As a group, equities analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.